



Your invitation to the
Heartland Advanced Practice Nurse Network

Monthly Meeting
 Sponsored by:



Genetic Insights Make Healthcare Personal

<p>Date & Time April 18, 2024 6:00PM</p>	<p>Location Pasta + Sauce 127 Main St, Cape Girardeau, MO 63701</p>	<p>To RSVP: Click Here Or Scan this QR Code</p> 
---	--	--





The GeneSight Psychotropic report may help you avoid multiple medication trials by providing information about which medications may require dose adjustments, be less likely to work, or have an increased risk of side effects based on your patient's genetic information. The report also includes information on how a patient's smoking status may affect their body's metabolism of certain medications.

GeneSight® Psychotropic Pharmacogenomic Test			
Patient, Sample Date of Birth: MMDD/YYYY Clinician: Georgia Clinician		Order Number: 000000 Report Date: MMDD/YYYY Reference: 000000	Questions about report interpretation? Contact our Medical Information team: 855.891.9415 medinfo@genesight.com
Antidepressants			
<input checked="" type="checkbox"/> Non-Smokers Smoking is defined as the daily inhalation of burning plant material (cigarettes, marijuana), and excludes vaping and e-cigarettes. This is used to determine medication results.			
Use as Directed	Moderate Gene-drug interaction	Significant Gene-drug interaction	
desipramine (Norpramin®)	venlafaxine (Effexor®)	bupropion (Wellbutrin®)	2
desvenlafaxine (Frisiv®)	selegiline (Emsam®)	amitriptyline (Elavil®)	3
levomilnacipran (Feldina®)	fluoxetine (Prozac®)	paroxetine (Paxil®)	4,6
nortriptyline (Pamelor®)	olomipramine (Anatan®)	escitalopram (Lexapro®)	1,4,6
trazodone (Desyre®)	fluvoxamine (Luvox®)	sertraline (Zoloft®)	1,4,6
vilazodone (Viibryd®)		imipramine (Tofran®)	1,6,7
vorfoxetine (Tymista®)		offalopram (Celexa®)	1,4,6,8
citalopram (Cymbalta®)		doxepin (Sinequan®)	1,6,7,8
mirfazapine (Remeron®)			



MyRisk with RiskScore® is a powerful tool that evaluates 48 genes associated with 11 different hereditary cancers. MyRisk helps any practice easily assess a patient's lifetime hereditary cancer risk and help improve patient outcomes with expert guidance, support, and personalized care plans.

Designed for patients of all ancestries, RiskScore is a component of the MyRisk test that analyzes family history, personal clinical risk factors, and genetic markers to estimate the risk of developing breast cancer over the next five years and remaining lifetime.



This event is not open to the general public. If you were not the original recipient of this invitation, please contact a GeneSight representative with your request to attend. This presentation is intended for appropriate medical healthcare providers.